Post-transplant lymphoproliferative disorder: a review (Q35079593)

6 August 2017

1 reference

title

Post-transplant lymphoproliferative disorder: a review (English)

1 reference

post-transplant lymphoproliferative disorder

6 August 2017

main subject

0 references

2

Porter DL

1 reference

6 August 2017

3

Stadtmauer EA

1 reference

6 August 2017

1

Loren AW

1 reference

6 August 2017

Tsai DE

4

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Bone Marrow Transplantation

6 August 2017

published in

1 reference

6 August 2017

volume

31

1 reference

6 August 2017

issue

3

1 reference

6 August 2017

page(s)

145-155

1 reference

Orthotopic homotransplantation of the human liver

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus (EBV) associated B-cell lymphoproliferative disease following HLA identical sibling marrow transplantation for aplastic anaemia in a patient with an EBV seronegative donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

The diagnosis and treatment of posttransplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: analysis of prognostic variables and long-term follow-up of 42 adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus-associated lymphoproliferative disorder after autologous bone marrow transplantation: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Post-transplant lymphoproliferative disorder after autologous peripheral stem cell transplantation in a pediatric patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Epstein-Barr virus-negative post-transplant lymphoproliferative disorders: a distinct entity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Early identification of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Predictive negative value of persistent low Epstein-Barr virus viral load after intestinal transplantation in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Interferon-alpha affects the immune response in post-transplant lymphoproliferative disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Durable remission after aggressive chemotherapy for very late post-kidney transplant lymphoproliferation: A report of 16 cases observed in a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Longitudinal dynamics of Epstein-Barr virus-specific cytotoxic T lymphocytes during posttransplant lymphoproliferative disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Autologous lymphokine-activated killer cell therapy of lymphoproliferative disorders arising in organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Reduced incidence of Epstein-Barr virus-associated posttransplant lymphoproliferative disorder using preemptive antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Anti-CD20 monoclonal antibody for post-transplant lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

Lymphoproliferative disorders following allogeneic bone marrow transplantation: the Vancouver experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

7 January 2021

Effect of acyclovir [9-(2-hydroxyethoxymethyl)guanine] on Epstein-Barr virus DNA replication

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

7 January 2021

Interferon-alpha treatment of posttransplant lymphoproliferative disorder in recipients of solid organ transplants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

7 January 2021

Treatment of B-lymphoproliferative disorder with a monoclonal anti-interleukin-6 antibody in 12 patients: a multicenter phase 1-2 clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

7 January 2021

Treatment of posttransplant lymphoproliferative disease in the central nervous system of a lung transplant recipient using allogeneic leukocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1703806

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1703806

1 reference

6 August 2017

1 reference